Home » Stocks » NBY » Company

NovaBay Pharmaceuticals, Inc. (NBY)

Stock Price: $0.655 USD 0.031 (5.02%)
Updated Jul 27, 2021 4:00 PM EDT - Market closed
NovaBay Pharmaceuticals, Inc.
Country United States
IPO Date Oct 26, 2007
Industry Biotechnology
Sector Healthcare
Employees 22
CEO Justin Hall

Contact Details

Address:2000 Powell St Ste 1150
Emeryville, California 94608-1804
United States
Phone 510 899 8800

Stock Information

Ticker Symbol NBY
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001389545
CUSIP Number 628729105
ISIN Number US66987P2011
Employer ID 68-0454536

Company Description

NovaBay Pharmaceuticals, Inc., a medical device company, develops products for the eye care markets in the United States and internationally.

The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx Clinical Reset, a gentle and soothing facial spray; and NeutroPhase and PhaseOne for the wound care market.

It also offers KN95 Masks. The company sells its products through distribution partners, as well as offers Avenova and CelleRx Clinical Reset through online sales channels.

The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Key Executives

Justin M. Hall Esq.President, Chief Executive Officer, General Counsel, Chief Compliance Officer, Corporate Secretary and Director
Andrew D. JonesChief Financial Officer and Treasurer